drugset / Trial / NCT00890565

Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)

NCT00890565

Phase 1 Completed 240 enrolled Kyowa Kirin, Inc.
RandomizedParallel-groupSingle-blindOther

Summary

This study aims to evaluate the electrocardiogram (ECG) effects of Sancuso® compared to placebo and moxifloxacin in healthy subjects.

Timeline

Start
2009-05
Primary completion
2009-08
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Granisetron Other / unclassified 10 ug/kg Other
Subject Granisetron Other / unclassified 3.1 mg Other
Subject Moxifloxacin Small molecule 400 mg Oral

Indications

No indication recorded.